Harvard Bioscience, Inc. — FY2012 Form 10-K
Business context and reporting period. The company develops, manufactures, distributes and markets life-science research instruments, apparatus and consumables worldwide. It reports a Life Science Research Tools (LSRT) business and a Regenerative Medicine Device (RMD) business. This annual filing covers the fiscal year ended December 31, 2012; fourth-quarter figures are unaudited.
Financial performance and liquidity
| Metric | FY2012 | FY2011 |
|---|---|---|
| Revenue | $111.2 million | $108.9 million |
| Gross profit / margin | $52.4 million / 47.2% | $50.3 million / 46.2% |
| Operating income / margin | $3.2 million / 2.8% | $6.1 million / 5.6% |
| Continuing-operations income | $1.5 million | $3.8 million |
| Net income / diluted EPS | $2.4 million / $0.08 | $3.8 million / $0.13 |
| Operating cash flow | $8.1 million | $6.6 million |
| Cash and working capital at year-end | $20.7 million / $49.1 million | $17.9 million / $48.0 million |
| Debt at year-end | $13.0 million | $16.3 million |
Capital expenditures were $1.8 million; operating cash flow less capital expenditures was approximately $6.3 million (calculated). The $20 million revolving facility had $7 million of unused capacity at year-end, bore interest at 3.21%, and matured August 7, 2014. The company reported compliance with its financial covenants. Its $20.7 million cash balance included $19.2 million held by foreign subsidiaries; management said these funds were intended for foreign operations and investment and were not available for U.S. operations without repatriation and potential tax.
Changes versus comparable periods
- Annual revenue rose 2.1%, but acquisitions contributed about $3.4 million and currency reduced revenue by about $1.2 million; reported organic growth excluding those effects was approximately 0.1%. Softer academic and government research demand and lower Hoefer sales to GE Healthcare weighed on results.
- Gross margin improved, mainly from a more favorable sales mix. Operating expenses increased to $49.3 million from $44.2 million, including higher RMD development spending. RMD recorded a $6.3 million operating loss, versus $3.0 million in 2011; LSRT operating income was $13.9 million.
- Operating cash flow increased, primarily reflecting year-over-year working-capital changes. Debt declined by $3.4 million.
- Fourth-quarter revenue was $28.2 million versus $29.0 million in Q4 2011. Operating income was $0.7 million versus $1.4 million. Q4 2012 net income was $1.2 million, including $0.8 million of income from discontinued operations; continuing-operations income was $0.4 million.
Outlook, commentary, risks and unusual items
- Management expected available cash, operating cash generation and debt capacity to fund current operations and capital expenditures for at least 12 months and beyond, based on current plans. It expected approximately $3.0 million in 2013 capital expenditures. No specific revenue or earnings guidance was provided.
- The company planned to continue RMD investment and expected to submit its clinical syringe-pump product to regulators in 2013. A proposed HART subsidiary IPO and subsequent pro-rata distribution to shareholders depended on the offering proceeding and the outcome of an IRS private-letter ruling; timing and completion were uncertain.
- The company recognized $0.8 million, net of tax, from a previously reserved earn-out related to a 2008 divestiture after determining collection was probable. The separate $4.6 million Digilab earn-out notes remained fully reserved due to uncertain collectability.
- Key risks include dependence on research funding and customer spending, international and foreign-exchange exposure, rising costs, acquisition integration, and the concentration of product distribution through GE Healthcare. GE agreements covering Biochrom and Hoefer were due to expire in December and September 2013, respectively; the company said it was discussing an extension of the Hoefer agreement.
- RMD products face regulatory, clinical, commercialization and product-liability risks and depend on external collaborators. One patient who received a regenerated trachea in 2011 died in March 2012; the recorded cause was pneumonia secondary to trachea cancer, and the company said it knew of no evidence that its scaffold or bioreactor contributed. A separate intellectual-property dispute arose when Nanofiber Solutions alleged possible misuse of confidential information and infringement; the company disputed the claims and did not expect a material adverse effect, while noting the matter was ongoing.
- The company reported an underfunded pension liability of $5.9 million, up from $4.9 million. It also reported effective disclosure controls and internal control over financial reporting; the auditor gave unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Whether core LSRT organic sales recover, particularly in academic/government markets and at Hoefer, and whether GE Healthcare renews the distribution agreements on acceptable terms.
- Whether RMD spending produces regulatory progress and commercial revenue, and whether the HART IPO, IRS ruling and contemplated shareholder distribution proceed.
- Cash accessibility and funding needs: most year-end cash was held overseas, while debt covenants, facility maturity and acquisition or development plans may affect liquidity.
- Resolution and potential consequences of the Nanofiber Solutions dispute, and the collectability of the separate reserved Digilab earn-out notes.
- The sustainability of earnings: FY2012 included $0.8 million from discontinued operations, while operating income fell despite higher revenue and gross margin.